SCHEMBL4250874

SCHEMBL4250874

NS(=O)(=O)CCc1ccncc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.59
KMT2A Q03164 2/20 0.53
NPC1 O15118 1/20 0.53
LOXL2 Q9Y4K0 2/20 0.52
CA2 P00918 3/20 0.46
HRH1 P35367 2/20 0.45
RAB9A P51151 1/20 0.44
ALDH1A1 P00352 3/20 0.44
TDP1 Q9NUW8 1/20 0.43
CA1 P00915 2/20 0.43
CA5A P35218 1/20 0.43
CA7 P43166 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ENPP1 P22413 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5515360 0.88 HRH1 (0.52) RECQLKMT2ANPC1LOXL2CA2
SCHEMBL1272595 0.78 KMT2A (0.53) KMT2ANPC1LOXL2HRH1RAB9A
SCHEMBL819155 0.78 KMT2A (0.53) KMT2ANPC1LOXL2CA2HRH1
SCHEMBL1272598 0.78 KMT2A (0.58) KMT2ANPC1LOXL2HRH1RAB9A
SCHEMBL2252187 0.78 KMT2A (0.53) KMT2ANPC1LOXL2HRH1RAB9A
SCHEMBL14194326 0.78 KMT2A (0.53) KMT2ANPC1LOXL2HRH1RAB9A
SCHEMBL4249313 0.78 LOXL2 (0.50) RECQLKMT2ANPC1LOXL2CA2
SCHEMBL988036 0.77 CA2 (0.60) KMT2ANPC1LOXL2CA2HRH1
SCHEMBL1644097 0.77 CA2 (0.70) RECQLLOXL2CA2ALDH1A1CA1
SCHEMBL9343853 0.77 KMT2A (0.56) KMT2ANPC1LOXL2CA2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049494-A2 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2009-04-22 EP claimed
WO-2008008310-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2008-01-17 WO claimed
US-11724997-B2 Compounds and compositions for treating conditions associated with APJ receptor activity ANNAPURNA BIO, INC. (US) 2023-08-15 US disclosed
US-11724997-B2 Compounds and compositions for treating conditions associated with APJ receptor activity ANNAPURNA BIO, INC. (US) 2023-08-15 US disclosed
US-20210053936-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY ANNAPURNA BIO, INC. 2021-02-25 US disclosed
CN-112055713-A Compounds and compositions for treating diseases associated with APJ receptor activity 安娜普尔纳生物股份有限公司 2020-12-08 CN disclosed
EP-3388425-B1 AMINOAZOLE DERIVATIVE TEIJIN PHARMA LTD (JP) 2020-08-05 EP disclosed
US-10689354-B2 Aminoazole derivative TEIJIN PHARMA LIMITED (JP) 2020-06-23 US disclosed
US-20190031628-A1 AMINOAZOLE DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2019-01-31 US disclosed
WO-2017099237-A1 AMINOAZOLE DERIVATIVE 帝人ファーマ株式会社 2017-06-15 WO disclosed
EP-2049494-A2 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2009-04-22 EP disclosed
EP-1735284-A1 N-(1-ARYLPYRAZOL-4L)SULFONAMIDES AND THEIR USE AS PARASITICIDES Pfizer Limited (GB) 2006-12-27 EP disclosed
WO-2005090313-A1 N-(1-ARYLPYRAZOL-4L)SULFONAMIDES AND THEIR USE AS PARASITICIDES PFIZER LIMITED (GB) 2005-09-29 WO disclosed
US-6887903-B1 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. (IT) 2005-05-03 US disclosed
US-6881755-B2 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them Dompé S.p.A. (IT) 2005-04-19 US disclosed
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. 2003-11-20 US disclosed
EP-1123276-B1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM DOMPE SPA (IT) 2003-01-08 EP disclosed
CN-1324344-A N- (2-aryl-propionyl) -sulfonamides and pharmaceutical compositions containing them DOMPE SPA (IT) 2001-11-28 CN disclosed
EP-1123276-A1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM Dompe' S.P.A. (IT) 2001-08-16 EP disclosed
WO-2000024710-A1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM DOMPE' S.P.A. (IT) 2000-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11724997-B2 Compounds and compositions for treating conditions associated with APJ receptor activity APLNR, AGTR1, AGTR2 RECQL 4047/4885KMT2A 2897/4885NPC1 2329/4885
US-20210053936-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY APLNR, AGTR1, AGTR2 RECQL 4047/4885KMT2A 2897/4885NPC1 2329/4885
US-10689354-B2 Aminoazole derivative AR, NR3C2, NR5A1 RECQL 4686/4885KMT2A 1490/4885NPC1 3244/4885
US-20190031628-A1 AMINOAZOLE DERIVATIVE AR, NR3C2, NR5A1 RECQL 4686/4885KMT2A 1490/4885NPC1 3244/4885
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them ELANE, MPO, FPR1 RECQL 2761/4885KMT2A 4179/4885NPC1 1760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.